Cancer Education · Research
Combining Immunotherapy With Local Treatment Advances Liver Cancer Care, While a Provocative New Question Emerges About Diabetes Drugs
For more than two decades, transarterial chemoembolization (TACE) has been the standard of care for unresectable hepatocellular carcinoma (HCC) eligible for embolization, typically producing a median progression-free survival of eight to ten months.
By Ursa Brown-Glaberman, MD
